NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES
THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.
- Dr. Fabrice NAVARRO, New Deal Project Coordinator
THE PROJECT GOALS
THE PROJECT GOALS
The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.
Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.
THE PROJECT NEWS
February New Deal Reads
Oral nanoparticles of SNX10-shRNA plasmids ameliorate Mouse Colitis. W.Bao, Q.Wu, B.Hu, D.Sun, S.Zhao, X.Shen, H.Cheng & W.Shen. Int [...]
January New Deal Reads
Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. [...]
IBD & Tea: what patients want to know when it comes to a clinical trial
Often, patients who live with Inflammatory Bowel Disease (IBD) do not respond to conventional drugs and are offered [...]
November New Deal Reads
Patient involvement in clinical research: why, when and how. Sacristán JA. Et al. Patient preference and adherence, volume [...]
THE PROJECT PARTNERS
THE PROJECT PARTNERS
